1. Norway Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
BerGenBio ASA

BerGenBio ASA

BRRGF
BerGenBio ASAUS flagOther OTC
97.09
USD
- -
- -
9.49BMarket Cap
BerGenBio ASA
BRRGF
(Other OTC)

Recent

price

97.09

P/E

ratio

- -

div

yld

- -

ROIC.AI

2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
0.01
- -
- -
- -
238.44
848.59
44.38
48.69
28.13
0.02
10.92
- -
1.54
Revenue per Share
-1.16
-7,887.44
-14,198.1
-21,792.61
-19,580.01
-19,000.57
-18,981.54
-19,460.53
-21,843.83
-8.52
-561.04
- -
-253.33
Basic EPS, GAAP
-1.08
-6,880.55
-13,626.01
-20,146.87
-19,088.53
-17,799.68
-17,307.22
-19,081.59
-20,839.49
-10.08
-359.13
- -
-278.72
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.05
271.17
368.52
597.06
558.66
582.38
644.41
556.46
641.02
3.57
-2,511.22
- -
-1,141.41
Book Value per Share
2.44
7,082.37
16,765.48
41,902.88
34,440.93
20,952.9
49,496.27
24,182.36
6,398.53
5.71
433.52
- -
197.04
Tangible Book Value per Share
50
- -
- -
- -
- -
- -
- -
- -
- -
22
- -
- -
1
Basic Weighted Avg Shares
1
- -
- -
- -
2
9
1
1
- -
- -
3
23
1
Sales/Revenue/Turnover
-9,836.79
- -
- -
- -
-8,331.43
-2,296.34
-43,442.93
-40,628.17
-78,569.41
-54,186.16
-5,211.07
-593.35
-17,833.73
Operating Margin (%)
- -
- -
- -
- -
- -
1
1
1
1
- -
15
11
- -
Depreciation Expense
-58
-72
-130
-182
-192
-199
-257
-309
-302
-190
-140
-155
-139
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-9,662.21
- -
- -
- -
-8,211.86
-2,239.08
-42,766.89
-39,969.51
-77,666.32
-53,785.59
-5,137.45
-673.13
-16,424.65
Profit Margin (%)
126
70
153
350
337
219
669
384
89
127
84
129
84
Working Capital
- -
1
- -
- -
- -
- -
1
1
- -
- -
5
1
5
LT Debt
122
65
153
350
337
220
670
384
88
127
108
146
108
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-2,946.75
-4,439.09
-4,358.52
-3,665.24
-3,442.06
-3,465.4
-3,521.1
-3,411.5
-430.28
-199.23
-159.9
-465.89
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Jun'24
Sep'24
Dec'24
ST Debt
- -
- -
3
LT Borrowings
- -
- -
1
LT Finance Leases
- -
- -
5
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1
1
1
Market Capitalization
28,424
28,272
1,565

Working Capital

FRC

•

in mil. unless spec.
Jun'24
Sep'24
Dec'24
Total Current Assets
218
195
142
Cash, Cash Equivalents & STI
200
175
131
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
43
41
58
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
3
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
37.62%
-11.11%
35.07%
Free Cash Flow
15.69%
-2.55%
44.84%
Net Income, GAAP
12.38%
-6.94%
10.61%
Sales/Revenue/Turnover
- -
277.02%
744.16%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
1
3
2025
- -
- -
- -
- -
23

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
-5,204.05
-929.73
-68.31
-1.01
-8.52
2024
-86.08
-88.83
-40.68
-46.94
-561.04
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
4D Molecular Therapeutics, Inc. (FDMT)
Anti-Microbial Savior BioteQ Co., Ltd (6864.TWO)
Estrella Immunopharma, Inc. (ESLA)
Bonus BioGroup Ltd. (BONS.TA)
Poltreg S.A. (PTG.WA)
Kubota Pharmaceutical Holdings Co., Ltd. (4596.T)
Business
BerGenBio ASA, a clinical-stage biopharmaceutical company focused on developing selective AXL inhibitors for aggressive diseases including advanced treatment-resistant cancers and severe respiratory infections, completed a statutory merger with Oncoinvent ASA on October 29, 2025, under which BerGenBio serves as the acquiring entity; the combined company was renamed Oncoinvent ASA and now advances Oncoinvent's late-stage oncology pipeline featuring radiopharmaceutical therapies alongside BerGenBio's prior assets. Prior to the merger, BerGenBio's core products encompassed bemcentinib (formerly BGB324), a first-in-class highly selective oral small molecule AXL kinase inhibitor in Phase II trials for non-small cell lung cancer, acute myeloid leukemia, and other solid tumors; BGB149, a wholly owned humanized anti-AXL monoclonal antibody in Phase I testing; and preclinical assets including an outlicensed AXL antibody for antibody-drug conjugate development with ADC Therapeutics SA; the company halted all bemcentinib development activities in early 2025 following closure of its lead BGBC016 trial in STK11-mutated NSCLC. The merger, approved by BerGenBio's Extraordinary General Meeting on August 4, 2025, integrates BerGenBio's capital resources and Oslo Stock Exchange listing (ticker shifted to ONCIN) with Oncoinvent's Radspherin, an alpha-emitting radiopharmaceutical microparticle therapy targeting peritoneal carcinomatosis in ovarian cancer and other abdominal malignancies via intraperitoneal administration; post-merger, a fully underwritten NOK 130 million rights issue commenced in November 2025 to fund clinical advancement, including Oncoinvent's ongoing randomized Phase 2 trial of Radspherin, with board and management transitioning to Oncoinvent's leadership plus BerGenBio's former CEO Olav Hellebø. Founded in 2007 and headquartered at Nygårdsgaten 114 in Bergen, Norway, BerGenBio (now Oncoinvent ASA) operates in the biotechnology sector serving global oncology and infectious disease markets through strategic partnerships, investigator-sponsored trials, and companion diagnostics for AXL-positive patient selection; the entity employs approximately 13 staff and maintains a lean structure post cost-containment measures implemented in 2025.

Company News

APIChatGPT